Gabriel E, Sukniam K, Popp K, Kowkabany G, Manaise H, Attwood K
Clin Transl Med. 2024; 14(4):e1633.
PMID: 38616706
PMC: 11016937.
DOI: 10.1002/ctm2.1633.
Huang S, Wang X, Zhu Y, Wang Y, Chen J, Zheng H
Cell Death Dis. 2023; 14(12):791.
PMID: 38044399
PMC: 10694132.
DOI: 10.1038/s41419-023-06274-1.
Ding J, Cui X, Chen H, Sun Y, Yu W, Luo J
Cancers (Basel). 2022; 14(7).
PMID: 35406411
PMC: 8996923.
DOI: 10.3390/cancers14071639.
Luo J, Zhong X, Peng Y, Hao C, Liang X, Yang Y
Bioact Mater. 2022; 13:179-190.
PMID: 35224300
PMC: 8843953.
DOI: 10.1016/j.bioactmat.2021.10.037.
Martini C, DeNichilo M, King D, Cockshell M, Ebert B, Dale B
BMC Cancer. 2021; 21(1):765.
PMID: 34215227
PMC: 8254274.
DOI: 10.1186/s12885-021-08482-4.
MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
Lim D, Cho J, Yun E, Lee A, Ryu H, Lee Y
Genes (Basel). 2020; 12(1).
PMID: 33374832
PMC: 7823537.
DOI: 10.3390/genes12010009.
Exploiting Cancer's Tactics to Make Cancer a Manageable Chronic Disease.
Afrasiabi K, Linskey M, Zhou Y
Cancers (Basel). 2020; 12(6).
PMID: 32580319
PMC: 7352192.
DOI: 10.3390/cancers12061649.
Advances and Prospects of Vasculogenic Mimicry in Glioma: A Potential New Therapeutic Target?.
Cai H, Liu W, Liu X, Li Z, Feng T, Xue Y
Onco Targets Ther. 2020; 13:4473-4483.
PMID: 32547078
PMC: 7247597.
DOI: 10.2147/OTT.S247855.
Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer.
Lim D, Do Y, Kwon B, Chang W, Lee M, Kim J
BMB Rep. 2020; 53(6):291-298.
PMID: 32438972
PMC: 7330806.
Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer.
Hulin J, Gubareva E, Jarzebska N, Rodionov R, Mangoni A, Tommasi S
Front Oncol. 2020; 9:1455.
PMID: 31993367
PMC: 6962312.
DOI: 10.3389/fonc.2019.01455.
Fact or Fiction, It Is Time for a Verdict on Vasculogenic Mimicry?.
Valdivia A, Mingo G, Aldana V, Pinto M, Ramirez M, Retamal C
Front Oncol. 2019; 9:680.
PMID: 31428573
PMC: 6688045.
DOI: 10.3389/fonc.2019.00680.
Correlations between quantitative parameters of contrast-enhanced ultrasound and vasculogenic mimicry in murine tumor model: a novel noninvasive technique for assessment?.
Zhou Y, Cai W, Li Y, Jiang X, Feng L, Zhu Q
Biol Proced Online. 2019; 21:11.
PMID: 31205452
PMC: 6560886.
DOI: 10.1186/s12575-019-0101-5.
HypoxamiRs Profiling Identify miR-765 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells.
Salinas-Vera Y, Gallardo-Rincon D, Garcia-Vazquez R, Hernandez-de la Cruz O, Marchat L, Gonzalez-Barrios J
Front Oncol. 2019; 9:381.
PMID: 31157166
PMC: 6528691.
DOI: 10.3389/fonc.2019.00381.
Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A, Qi Q, Peng X, Yan L, Takabe K, Hait N
Int J Oncol. 2019; 55(1):116-130.
PMID: 31059004
PMC: 6561627.
DOI: 10.3892/ijo.2019.4796.
Long Non-coding RNA LINC00339 Stimulates Glioma Vasculogenic Mimicry Formation by Regulating the miR-539-5p/TWIST1/MMPs Axis.
Guo J, Cai H, Liu X, Zheng J, Liu Y, Gong W
Mol Ther Nucleic Acids. 2018; 10:170-186.
PMID: 29499931
PMC: 5751969.
DOI: 10.1016/j.omtn.2017.11.011.
Structural and functional identification of vasculogenic mimicry in vitro.
Racordon D, Valdivia A, Mingo G, Erices R, Aravena R, Santoro F
Sci Rep. 2017; 7(1):6985.
PMID: 28765613
PMC: 5539303.
DOI: 10.1038/s41598-017-07622-w.
Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma.
Angara K, Borin T, Arbab A
Transl Oncol. 2017; 10(4):650-660.
PMID: 28668763
PMC: 5496207.
DOI: 10.1016/j.tranon.2017.04.007.
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.
Kanska J, Aspuria P, Taylor-Harding B, Spurka L, Funari V, Orsulic S
Oncotarget. 2017; 8(16):26200-26220.
PMID: 28412735
PMC: 5432250.
DOI: 10.18632/oncotarget.15429.
Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation .
Gao S, Fan C, Huang H, Zhu C, Su M, Zhang Y
Oncol Lett. 2016; 12(1):459-466.
PMID: 27347165
PMC: 4907296.
DOI: 10.3892/ol.2016.4630.
cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.
Tang J, Wang J, Fan L, Li X, Liu N, Luo W
Oncotarget. 2016; 7(17):24050-62.
PMID: 26992227
PMC: 5029683.
DOI: 10.18632/oncotarget.8079.